

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnosics Advisory Committee (DAC)

Minutes of the Meeting on 15 June 2016, 10:30 - 16:00

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

PRESENT:

Standing Committee members:

Dr Mark Kroese (Chairman)
Mrs Alexandria Moseley
Professor Anthony Wierzbicki
Professor Christopher Hyde
Dr Jim Gray
Mr John Bagshaw
Mr John Hitchman
Professor Mark Sculpher
Dr Michael Messenger
Dr Phil Chambers
Professor Ron Akehurst
Dr Simon Richards
Dr Steve Edwards
Dr Steve Thomas
Dr Sue Crawford

Standing Committee apologies:

Professor Adrian Newland
Dr Deirdre Ryan
Dr Dermot Neely
Professor Erika Denton
Mr Patrick McGinley
Dr Peter Naylor
Dr Simon Fleming

NICE staff in attendance:

Mirella Marlow, Programme Director, DAP
Carla Deakin, Associate Director, DAP
Frances Nixon, Technical Analyst, DAP
Rebecca Albrow, Technical Advisor, DAP
Robert Fernley, Project Manager, DAP
Nick Lowe, Administrator, DAP
Christopher Pomfrett, Technical Adviser, MTEP

Observing:

Elaine Chesworth, Medical Technology Implementation Manager, NICE
Hiral Shah, Technical Analyst, NICE
Jane Lynn, Business Analyst, NICE
Ruth Walker, Student, Centre for Reviews and Dissemination, York University
Thomas Walker, Technical Analyst, DAP, NICE

1. Introduction to the meeting

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

2. Code of conduct for members of the public attending the meeting

The Chairman explained the code of conduct to the members of the public attending this meeting.

3. Any other business

No other business was offered.

4. Minutes from the last Committee meeting

The Committee agreed the minutes from the **10 February 2016** Committee meeting.

5. NICE's advisory body guide to declaring a conflict of interest

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

High-throughput, non-invasive prenatal testing (NIPT) for fetal rhesus D status

External Assessment Group representatives: Centre for Reviews and Dissemination, York

Dr Huiqin Yang, Research Fellow, Centre for Reviews and Dissemination, York

Dr Pedro Saramago-Goncalves, Research Fellow, Centre for Health Economics, York

Dr Susan Griffin, Senior Research Fellow, Centre for Health Economics, York

Specialist Committee members:

Dr Alec McEwan, Subspecialist in Fetal Medicine, Nottingham University Hospitals NHS Trust

Ms Jenny Ford, Midwifery Matron, St Michaels Hospital

Dr Ruth Gottstein, Consultant Neonatologist, St. Mary's Hospital

Dr Samantha Revill, Lay Specialist Committee Member

Dr Sue Robinson, Consultant Haematologist, Guy's and St Thomas' NHS Foundation

Specialist Committee members apologies:

Mrs Joanna Davis, Senior Antenatal Screening Scientist, Nottingham University Hospital

PART 1 AND PART 2 (open and closed parts of the meeting).

Part 1 – Open session

The Chair welcomed representatives from **International Blood Group Reference Laboratory**.

There was **1** public attendee.

The Chair asked Committee members to declare any relevant interests.

- Mark Kroese declared a personal non-specific, non-pecuniary interest; this interest did not preclude him from taking part in the meeting.
- Mark Sculpher declared a personal specific non-pecuniary interest; this interest did not preclude him from taking part in the meeting.
- Sue Robinson declared a non-specific personal pecuniary interest; this interest did not preclude her from taking part in the meeting.
- Ruth Gottstein declared a specific non-personal pecuniary interest; this interest did not preclude her from taking part in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of high-throughput, non-invasive prenatal testing (NIPT) for fetal rhesus D status.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

End of Part 1

Part 2a – closed session

The Committee proceeded to discuss confidential details on the cost effectiveness of high-throughput, non-invasive prenatal testing (NIPT) for fetal rhesus D status with the manufacturer and external assessment group present.

Part 2 – closed session

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the Committee.

End of Part 2

Date, time and venue of next meeting

20 July 2016, 10:30 – 16:00, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD